Header Logo
Keywords
Last Name
Institution
Announcement

You can now add alternative names! Click here to add other names that you've published under.

A Phase IIIb/IV Safety Trial of Flat Dose Nivolumab in Combination with Ipilimumab in Participants with Non-Small Cell Lung Cancer (CheckMate 817, CHECKpoint pathway and nivoluMAb clinical Trial Evaluation)


Collapse Overview 
Collapse sponsor award id
CA209817


Collapse Biography 

Collapse Time 
Collapse start date
2018-09-13